Overview

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

Status:
Terminated
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Eli Lilly and Company
Collaborators:
AstraZeneca
Eli Lilly and Company